

March 3, 2016



## Trevena to Present at Three Upcoming Investor Events in March

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be presenting at the Cowen 36th Annual Health Care Conference in Boston, the 28th Annual ROTH Conference in Orange County, and the Barclays Global Healthcare Conference in Miami. Details of the conferences are as follows:

### **Cowen 36th Annual Health Care Conference**

Date: Wednesday, March 9

Location: Boston, MA

Presentation Time: 10:00 am ET, 7:00 am PT

### **28th Annual ROTH Conference**

Date: Monday, March 14

Location: Orange County, CA

Presentation Time: 1:00 pm ET, 10:00 am PT

### **Barclays Global Healthcare Conference**

Date: Wednesday, March 16

Location: Miami, FL

Presentation Time: 3:20 pm ET, 12:20 pm PT

All three presentations will be webcast live, and can be accessed through the "Investors" section of the Company's website at [www.trevenainc.com](http://www.trevenainc.com). Following the conclusion of the presentations, each webcast will be archived and available for replay for 30 days.

### **About Trevena**

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates – oliceridine (TRV130) to treat moderate to severe acute pain intravenously (Phase 3), TRV027 to treat acute heart failure (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160303005200/en/>

Trevena, Inc.

Jonathan Violin, Ph.D., 610-354-8840 x231

Sr. Director, Investor Relations

[jviolin@trevenainc.com](mailto:jviolin@trevenainc.com)

Source: Trevena, Inc.